NeuImmune, Inc. develops glycoengineered CHO cell lines to produce human-like glycoforms of therapeutic proteins, specifically targeting enzyme replacement therapies for lysosomal storage disorders. Their ICAM-1 targeting technology enhances cellular delivery and enzymatic activity, improving treatment efficacy for conditions with unmet medical needs.
Funding
Funding not disclosed
Founders
Product
Problem
Enzyme replacement therapies for lysosomal storage disorders often suffer from suboptimal cellular delivery and enzymatic activity, limiting their effectiveness in treating conditions with unmet medical needs. Current therapies may require high doses and frequent administration, potentially leading to hypersensitivity and resistance.
Solution
NeuImmune develops glycoengineered CHO (geCHO) cell lines designed to produce therapeutic proteins with human-like glycoforms, enhancing their efficacy in enzyme replacement therapies. Their geCHO BioDesign Platform allows for the uniform production of diverse glycoforms, while AI platforms identify optimal glycoforms for desired functional activity and bioproduction optimization. NeuImmune's ICAM-1 targeting technology further enhances cellular delivery and enzymatic activity by combining geCHO proteins with an ICAM-1-binding peptide. This approach enables efficient access to the central nervous system (CNS) and visceral organs via intravenous dosing, potentially reducing the required dose and frequency, and lowering the risk of hypersensitivity and resistance.
Target Audience
NeuImmune's primary target audience includes pharmaceutical companies developing enzyme replacement therapies for lysosomal storage disorders and other related conditions with unmet medical needs.
Features
- geCHO BioDesign Platform: A panel of glycoengineered CHO cells for producing human-like glycoforms of therapeutic proteins.
- AI-driven glycoform identification: Utilizes AI platforms to identify optimal glycoforms associated with desired functional activity.
- ICAM-1 Targeting Technology: Combines geCHO proteins with an ICAM-1-binding peptide to enhance cellular delivery.
- Enhanced CNS and visceral organ access: Enables efficient access to target organs via intravenous dosing.
- Reduced dose and frequency: Aims to lower the required dose and frequency of enzyme replacement therapies.
- Lowered risk of hypersensitivity and resistance: Designed to reduce the potential for adverse reactions.